Medeze Group PCL (BKK:MEDEZE)

Thailand · Delayed Price · Currency is THB

6.40

-0.10 (-1.54%)

Last updated: Sep 2, 2026, 4:24 PM ICT

-3.76% (1Y)

Market Cap	6.84B -3.8%
Revenue (ttm)	714.44M -18.3%
Net Income	141.51M -56.1%
EPS	0.13 -59.1%
Shares Out	1.07B
PE Ratio	48.30
Forward PE	29.09
Dividend	0.16 (2.42%)
Ex-Dividend Date	Apr 29, 2026

Volume	146,620
Open	6.50
Previous Close	6.50
Day's Range	6.40 - 6.50
52-Week Range	6.00 - 7.45
Beta	n/a
Analysts	Buy
Price Target	8.05 (+25.78%)
Earnings Date	Nov 12, 2026

About Medeze Group PCL

Medeze Group Public Company Limited engages in collection and storage of stem cells for use in medication in Thailand, Vietnam, Cambodia, Philippines, and internationally. The company operates through four segments: Stem Cells; Natural Killer Cells; Others; and Sales of Products. It also provides sorting, cultivation, and development of stem cells; testing services to test the performance and count the number of natural killer cells. In addition, the company is involved in research, develops, and collects data on all types of human cellular act... [Read more]

Industry Medical Care Facilities

Sector Healthcare

Founded 2010

Employees 200

Stock Exchange Stock Exchange of Thailand

Ticker Symbol MEDEZE

Full Company Profile

Financial Performance

In 2025, Medeze Group PCL's revenue was 776.41 million, a decrease of -11.15% compared to the previous year's 873.87 million. Earnings were 196.38 million, a decrease of -42.03%.

Financial Statements

Analyst Summary

According to 2 analysts, the average rating for MEDEZE stock is "Buy." The 12-month stock price target is ฿8.05, which is an increase of 25.78% from the latest price.

Price Target

฿8.05

(25.78% upside)

Analyst Consensus: Buy

Stock Forecasts